Introduction {#s1}
============

Lung cancer is the leading cause of cancer-related deaths worldwide. In the U.S. the number of new occurrences is approximately annually, and the number of deaths is , representing of all cancer related deaths [@pone.0053663-Siegel1]. Lack of early detection and limited options for target therapies are both contributing factors to the dismal statistics observed in lung cancer. Thus, advances in both of these areas are likely to lead to improved outcomes.

microRNAs (miRs or miRNAs) represent a class of non-coding RNAs that have the capacity for gene regulation and may serve as diagnostic and prognostic biomarkers in lung cancer. Abnormal expression patterns for miRNAs have been identified in lung cancers. Specifically, let-7 and miR-9 are deregulated in both lung cancers and other solid malignancies. Takamizawa et al. (2004) and Nicoloso et al. (2009) demonstrated that let-7 is downregulated in non-small cell lung cancers (NSCLC) [@pone.0053663-Takamizawa1], [@pone.0053663-Nicoloso1]. Several investigators have shown that let-7 harbors tumor suppressive properties both in vitro and in vivo [@pone.0053663-Trang1], [@pone.0053663-Trang2]. Using microarray data, Yanaihara et al. (2006) reported that miR-9 was decreased in NSCLC [@pone.0053663-Yanaihara1], whereas Volinia et al. (2006) reported an increase in miR-9 expression [@pone.0053663-Volinia1]. More recently Crawford et al. (2009) reported increased expression of miR-9 in NSCLC [@pone.0053663-Crawford1], and Võsa et al. (2011) drew the same conclusion from their microarray data [@pone.0053663-Vsa1]. Recently, we have also independently analyzed cases of NSCLC and compared miR-9 expression between tumors and adjacent uninvolved lung tissue. We found that in approximately cases miR-9 was overexpressed in lung tumors; see Supplementary [Material S1](#pone.0053663.s001){ref-type="supplementary-material"}. A recent investigation showed that miR-9 contributes to metastatic potential in breast cancer in part by targeting components of epithelial mesenchymal transition (EMT) [@pone.0053663-Ma1]. However, the role for miR-9 in the pathogenesis of lung cancer is less well understood. Mascaux et al. (2009) demonstrated an induction in miR-9 expression during bronchial squamous carcinogenesis [@pone.0053663-Mascaux1].

Given the fact that a single miRNA may regulate tens to hundreds of genes, understanding the importance of an individual miRNA in cancer biology can be challenging. This is further complicated by observations that the dysregulation of several miRNAs is often required to cause a given phenotype. To date, few models exist to elucidate the mechanisms by which multiple miRNAs contribute both individually and in tandem to promote tumor initiation and progression. Applying mathematical modeling to miRNA biology provides an opportunity to understand these complex relationships. In the current study, we have developed for the first time a mathematical model focusing on miRNAs (miR-9 and let-7) in the context of lung cancer as a model system; however, our model system could be applicable to miRNA biology in both malignant and benign diseases. For simplicity, we have integrated these miRNAs into a signaling pathway to generate an in silico model for the process of EMT. Herein, we include the EGF-EGFR complex and associated downstream signaling culminating in matrix metalloproteinase (MMP) expression. Other components of our pathway include SOS, Ras, ERK, MYC,E-Cadherin, miR-9, and let-7.

We have simulated the model under several scenarios of gene mutations that may lead to lung cancer and determined, in each scenario, that miR-9 was upregulated and let-7 downregulated. We have also shown that the process leading to EMT is somewhat robust against random input into miR-9 and more strongly robust against random input into let-7.

Results {#s2}
=======

Biological Background {#s2a}
---------------------

[Figure 1 A](#pone-0053663-g001){ref-type="fig"} shows a signaling pathway involving miR-9, let-7, MYC, and EMT, while [Figure 1 B](#pone-0053663-g001){ref-type="fig"} is a simplified version that will be used in the mathematical model. miR-9 is upregulated in NSCLC. Although Yanaihara et al. (2006) reported a decrease of miR-9 using microarray data [@pone.0053663-Yanaihara1], several other papers, some more recent, reported an increase of miR-9 in NSCLC: Volinia et al. (2006) and Võsa et al. (2011) used microarray [@pone.0053663-Volinia1], [@pone.0053663-Vsa1], and Crawford et al. (2009) used PCR [@pone.0053663-Crawford1]. We have analyzed cases of NSCLC with PCR and demonstrate miR-9 overexpression in lung tumors compared to adjacent uninvolved lung and present a representation of such cases; see Supplementary [Material S1](#pone.0053663.s001){ref-type="supplementary-material"}.

![A signaling pathway for lung cancer.\
A pathway from EGF-EGFR complex to MMP, which includes miR-9 and let-7, is given in (A) and a simplified pathway is shown in (B).](pone.0053663.g001){#pone-0053663-g001}

MYC controls many fundamental cellular processes, and aberrant MYC expression is known to be associated with cancer. For example, Frenzel et al. (2010) observed that MYC is usually activated in many cancers [@pone.0053663-Frenzel1], and Aguda et al. (2008) showed how MYC can act as either an oncogene or tumor suppressor [@pone.0053663-Aguda1]. In lung cancer, MYC family oncogenes are amplified in both small-cell lung cancers (SCLC) and NSCLC [@pone.0053663-Yokota1], [@pone.0053663-Broers1]. Moreover, c-MYC can induce metastasis in c-Raf mutant NSCLC [@pone.0053663-Rapp1].

Investigators have also identified a link between MYC and miRNAs that also play a significant role in cancer. Rinaldi et al. (2007) showed that both MYC and the miRNA cluster miR-17-92 are amplified in human mantle cell lymphoma [@pone.0053663-Rinaldi1]; Frenzel et al. (2010) described miR-9 as an oncogenic miRNA and let-7 as a tumor suppressor miRNA both of which are regulated by MYC [@pone.0053663-Frenzel1]: MYC induces miR-9, which blocks tumor suppressor pathways, while MYC inhibits let-7, which blocks oncogenic pathways. Ma et al. (2010) found that miR-9 is driven by MYC, downregulates E-Cadherin, and induces metastasis in breast cancer [@pone.0053663-Ma1]. Wolfer and Ramaswamy (2011) investigated the role of MYC in breast cancer metastasis using a signaling pathway that includes let-7, miR-9, E-Cadherin, and EMT [@pone.0053663-Wolfer1].

Our proposed pathway is based on several lines of investigation. Similar to breast cancer, let-7 is downregulated in NSCLC [@pone.0053663-Takamizawa1], [@pone.0053663-Nicoloso1]. Takamizawa et al. (2004) demonstrated that reductions of let-7 as high as occurred in tumors compared to uninvolved adjacent lung tissue [@pone.0053663-Takamizawa1]. In this same study, only cases had such reductions (). However, more recent investigation by Inamura et al. (2007) demonstrated that among well-differentiated adenocarcinomas (), the reductions in let-7 family members were more modest (approximately ) [@pone.0053663-Inamura1]. Wang et al. (2011) asserted that c-MYC represses transcription of let-7 [@pone.0053663-Wang1]. Johnson et al. (2005) and others showed that Ras is suppressed by let-7 [@pone.0053663-Johnson1]. Lee and Dutta (2007) suggested that let-7 represses HMGA-2 in a lung cancer cell [@pone.0053663-Lee1], and Thuault et al. (2008) asserted that HMGA-2 causes EMT by activating Snail1 which in turn represses E-Cadherin [@pone.0053663-Thuault1]. E-Cadherin downregulates MMP in bronchial tumor cells [@pone.0053663-NawrockiRaby1]. Both E-Cadherin and MMP have been implicated as biomarkers in several solid malignancies including lung cancer. A recent investigation showed that elevated levels of MMP-9 in cases of NSCLC correlated with advanced stages and the presence of metastases [@pone.0053663-Zheng1]. In addition Rao et al. (2005) demonstrated in vitro and in vivo that adenoviral mediated gene transfer of MMP-9 could reduce lung cancer invasive capacity and formation of metastases [@pone.0053663-Rao1]. Decreased E-Cadherin expression also appears to correlate with clinically more aggressive disease [@pone.0053663-Sulzer1]--[@pone.0053663-Saad1].

Roberts and Der (2007) used an EGFR-Ras-Raf-MEK-ERK pathway to explain that 10% of NSCLC arise from EGFR mutations and that 30% of NSCLC arise from mutations in Ras [@pone.0053663-Roberts1]. SOS is an intermediate between the EGF-EGFR complex and Ras [@pone.0053663-Zhao1], and is repressed through negative feedback by ERK [@pone.0053663-Brown1], [@pone.0053663-Orton1]. Huang et al. (2011) showed that ERK/MAPK in lung cancer activates c-MYC [@pone.0053663-Huang1]. [Figure 1 A](#pone-0053663-g001){ref-type="fig"} provides a summary of the above lines of investigation. For the purposes of simplicity, we propose a simpler version in [Figure 1 B](#pone-0053663-g001){ref-type="fig"} which nevertheless encompasses the main features of [Figure 1 A](#pone-0053663-g001){ref-type="fig"}. We recognize that other signaling pathways are driven by the EGF-EGFR complex including PI3K/Akt which regulates cell survival. However, given our interest in miR-9 and let-7 as potential biomarkers, we have not included this pathway in our model.

Model Equations {#s2b}
---------------

We introduce a system of ordinary differential equations that describe a signaling pathway of EMT (represented by the level of MMP mRNA) induced by MYC through miR-9 and let-7 as shown in [Figure 1 B](#pone-0053663-g001){ref-type="fig"}. The differential equations are based on [Figure 1 B](#pone-0053663-g001){ref-type="fig"}, and detailed explanations are given in [Methods](#s4){ref-type="sec"}. Notation for species concentrations is given in [Table 1](#pone-0053663-t001){ref-type="table"}.

10.1371/journal.pone.0053663.t001

###### Notation for species concentrations.

![](pone.0053663.t001){#pone-0053663-t001-1}

  Notation            Description
  ---------- -----------------------------
              EGF-EGFR complex (constant)
               active SOS concentration
               active Ras concentration
               active ERK concentration
               MYC protein concentration
                  miR-9 concentration
                  let-7 concentration
               E-Cadherin concentration
                MMP mRNA concentration

The table gives notation for species concentrations that are used in the mathematical model.

Simulations {#s2c}
-----------

A large number of NSCLC cases arise from EGFR mutations [@pone.0053663-Zhang1], [@pone.0053663-daCunhaSantos1] or Ras mutations [@pone.0053663-Adjei1]. We assume that negative feedback of ERK to SOS may be disrupted in NSCLC. We describe these aberrations by increasing , increasing , or decreasing , so that concentration level of EGF-EGFR complex increases, Ras is over-activated by SOS, or negative feedback of ERK to SOS is weakened. The following simulations demonstrate the effect of increase in and in and decrease in on the increase in miR-9, let-7 and MMP.

Simulations of the model equations were performed using Matlab. We used an ode solver, ode15 s, to solve a system of ordinary differential equations numerically. To solve a system of stochastic differential equations with random inputs in miR-9 or let-7 numerically, we developed a code using an Euler scheme. All initial values are taken to be those of healthy normal cells, namely, , , , , , , , and .

If increases as a result of mutations in EGFR, we expect an increase in miR-9 and a decrease in let-7 as indeed are observed in lung cancer. There will also be an increase in MMP mRNA signifying EMT and cell migration, which contributes to metastasis. [Figure 2](#pone-0053663-g002){ref-type="fig"} shows the level of miR-9, let-7, and MMP at as a function of : as increases, miR-9 and MMP mRNA concentrations increase and let-7 concentration decreases. For example, for , the level of miR-9 increases by -fold from to and that of MMP mRNA concentration increases by -fold from to compared to the level in healthy normal cells. On the other hand, the level of let-7 concentration decreases by -fold from to .

![Concentration changes of miR-9, let-7, and MMP mRNA with different values for\
**.** The units on the vertical axes are in and the time is at .](pone.0053663.g002){#pone-0053663-g002}

[Figure 3](#pone-0053663-g003){ref-type="fig"} shows the effect of Ras mutations on the levels of miR-9, let-7, and MMP mRNA after . Ras mutations are represented by an increase in . We see that as increases, so do the concentrations of miR-9 and MMP mRNA while let-7 concentration decreases. For example, for , the level of miR-9 concentration increases by -fold from to and that of MMP mRNA concentration increases by -fold from to compared to the level in healthy normal cells. On the other hand, the level of let-7 concentration decreases by -fold from to .

![Concentration changes of miR-9, let-7, and MMP mRNA with different values for\
**.** The units on the vertical axes are in and the time is at .](pone.0053663.g003){#pone-0053663-g003}

When the negative feedback of ERK to SOS is weakened as a result of possible mutations in ERK, the parameter in [Eq. (1)](#pone.0053663.e014){ref-type="disp-formula"} is decreased. [Figure 4](#pone-0053663-g004){ref-type="fig"} shows the effect of these mutations: as decreases, the concentrations of miR-9 and MMP increase and that of let-7 decreases. For example, for , the level of miR-9 concentration increases by -fold from to and that of MMP mRNA concentration increases by -fold from to compared to the level in healthy normal cells. On the other hand, the level of let-7 concentration decreases by -fold from to .

![Concentration changes of miR-9, let-7, and MMP mRNA with different values for\
**.** The units on the vertical axes are in and the time is at .](pone.0053663.g004){#pone-0053663-g004}

In [Figure 5](#pone-0053663-g005){ref-type="fig"}, we simulate the time evolution of SOS, Ras, ERK, MYC, miR-9, let-7, E-Cadherin, and MMP mRNA over a period of with ; in [Figure 6](#pone-0053663-g006){ref-type="fig"} the simulations are carried out for the longer period of . A comparison between the panels of the two figures shows that the dynamics of SOS, Ras, and ERK are very fast; MYC, miR-9, and let-7 change relatively slower, and MMP mRNA takes even longer to reach equilibrium. After minutes, SOS and Ras increased by -fold from to and from to , respectively; ERK and MYC increased by -fold from to and from to , respectively; miR-9 increased by -fold from to ; MMP increased by -fold from to compared to their values in normal cells; let-7 decreased by -fold from to , and E-Cadherin decreased by -fold from to .

![Simulation results for a cancer cell with EGFR mutations,\
**.** Time is from to ; initial values are those of a normal healthy cell; the units on the vertical axes are in and the units on the horizontal axes are in minutes.](pone.0053663.g005){#pone-0053663-g005}

![Simulation results for a cancer cell with EGFR mutations,\
**.** Time is from to ; initial values are those of a normal healthy cell; the units on the vertical axes are in and the units on the horizontal axes are scaled in minutes.](pone.0053663.g006){#pone-0053663-g006}

[Figures 7](#pone-0053663-g007){ref-type="fig"} and [8](#pone-0053663-g008){ref-type="fig"} show similar simulations when is increased to and [Figures 9](#pone-0053663-g009){ref-type="fig"} and [10](#pone-0053663-g010){ref-type="fig"} show similar simulations when is decreased to . In [Figure 8](#pone-0053663-g008){ref-type="fig"}, Ras increased by -fold from to ; ERK and MYC increased by -fold from to and from to , respectively; miR-9 increased by -fold from to ; MMP increased by -fold from to compared to their values in normal cells; SOS decreased by -fold from to ; let-7 decreased by -fold from to , and E-Cadherin decreased by -fold from to . In [Figure 10](#pone-0053663-g010){ref-type="fig"}, concentration changes essentially in the same amount as in [Figure 6](#pone-0053663-g006){ref-type="fig"}.

![Simulation results for a cancer cell with Ras mutations,\
**.** Time is from to ; initial values are those of a normal healthy cell; the units on the vertical axes are in and the units on the horizontal axes are in minutes.](pone.0053663.g007){#pone-0053663-g007}

![Simulation results for a cancer cell with Ras mutations,\
**.** Time is from to ; initial values are those of a normal healthy cell; the units on the vertical axes are in and the units on the horizontal axes are scaled in minutes.](pone.0053663.g008){#pone-0053663-g008}

![Simulation results for a cancer cell with disruption in the negative feedback from ERK to SOS,\
**.** Time is from to ; initial values are those of a normal healthy cell; the units on the vertical axes are in and the units on the horizontal axes are in minutes.](pone.0053663.g009){#pone-0053663-g009}

![Simulation results for a cancer cell with disruption in the negative feedback from ERK to SOS,\
**.** Time is from to ; initial values are those of a normal healthy cell; the units on the vertical axes are in and the units on the horizontal axes are scaled in minutes.](pone.0053663.g010){#pone-0053663-g010}

It would be interesting to study the effect of a 'background' on miR-9 and let-7, namely, the genes with whom these miRNAs interact. Such interactions however, are not reported in the literature. We therefore model such interactions by a random input. [Figure 11](#pone-0053663-g011){ref-type="fig"} shows how random perturbations of miR-9 affect MMP (EMT). Setting and as given in [Figure 2](#pone-0053663-g002){ref-type="fig"}, miR-9 perturbed by random Gaussian input and MMP are shown in [Figure 11 A--D and E--H](#pone-0053663-g011){ref-type="fig"}, respectively (we added on the right-hand side of where is a standard Brownian motion). Panels A/B and E/F in [Figure 11](#pone-0053663-g011){ref-type="fig"} correspond to the case when miR-9 is perturbed by Gaussian input with and Panels C/D and G/H in [Figure 11](#pone-0053663-g011){ref-type="fig"} correspond to the case when we increase to . In Panels B/D/F/H in [Figure 11](#pone-0053663-g011){ref-type="fig"}, we compare MMP concentration with random perturbations (red line) and without perturbations (green dotted line). [Figure 12](#pone-0053663-g012){ref-type="fig"} shows similar results in the case of let-7 with and . Panels A/B and E/F in [Figure 12](#pone-0053663-g012){ref-type="fig"} correspond to the case when let-7 is perturbed by Gaussian input with and Panels C/D and G/H in [Figure 12](#pone-0053663-g012){ref-type="fig"} correspond to the case when we increase to . [Figures 13](#pone-0053663-g013){ref-type="fig"} and [14](#pone-0053663-g014){ref-type="fig"} show means (blue or red line) and standard deviations (black dotted line) from the means of miR-9, let-7, and MMP concentrations obtained from realizations of simulation with the same parameters in [Figures 11](#pone-0053663-g011){ref-type="fig"} and [12](#pone-0053663-g012){ref-type="fig"}. Simulation results in [Figures 11](#pone-0053663-g011){ref-type="fig"}-[14](#pone-0053663-g014){ref-type="fig"} are obtained with fixed time step, .

![One sample path of miR-9 and MMP concentrations in time with random input in miR-9.\
For (A--D) and for (E--H) . For (A, B, E, F) and for (C, D, G, H) . The units on the horizontal axes are scaled in minutes.](pone.0053663.g011){#pone-0053663-g011}

![One sample path of let-7 and MMP concentrations in time with random input in let-7.\
For (A--D) and for (E--H) . For (A, B, E, F) and for (C, D, G, H) . The units on the horizontal axes are scaled in minutes.](pone.0053663.g012){#pone-0053663-g012}

![Mean concentrations of miR-9 and MMP and standard deviations from the means in time with random input in miR-9.\
For (A--D) and for (E--H) . For (A, B, E, F) and for (C, D, G, H) . The units on the horizontal axes are scaled in minutes. The result is taken from realizations of simulation.](pone.0053663.g013){#pone-0053663-g013}

![Mean concentrations of let-7 and MMP and standard deviations from the means in time with random input in let-7.\
For (A--D) and for (E--H) . For (A, B, E, F) and for (C, D, G, H) . The units on the horizontal axes are scaled in minutes. The result is taken from realizations of simulation.](pone.0053663.g014){#pone-0053663-g014}

We conclude that mean MMP concentrations and standard deviations from the means are stable (robust) to small perturbations in miR-9, i.e. when . However, when we increase already to stability of standard deviations from the mean MMP concentration tends to break down as we see from Panels D/H in [Figure 13](#pone-0053663-g013){ref-type="fig"}; Panels D/H in [Figure 11](#pone-0053663-g011){ref-type="fig"} show one sample path of unstable MMP concentration against miR-9 perturbation. On the other hand, mean MMP concentrations and standard deviations from the means are much more stable for let-7 perturbations with large , and trajectories of means closely follow the trajectory of MMP without random input as shown in [Figure 14](#pone-0053663-g014){ref-type="fig"}; [Figure 12](#pone-0053663-g012){ref-type="fig"} shows one sample path of MMP concentration against let-7 perturbation. Notice that we have taken in Panels A/B/E/F and in Panels C/D/G/H. For let-7, if we take as small as as we did in Panels C/D/G/H in [Figure 11](#pone-0053663-g011){ref-type="fig"}, standard deviations are very small and negligible (not shown here). The reason why MMP is more stable against random perturbations of let-7 than against miR-9 perturbations is that let-7 perturbations undergo damping by the negative feedbacks from let-7 to Ras and from ERK to SOS, as shown in [Figure 1](#pone-0053663-g001){ref-type="fig"}. Similar results (not shown here) hold when we vary or , instead of .

Sensitivity Analysis {#s2d}
--------------------

Since we are focusing on miR-9 upregulation and let-7 downregulation as potential biomarkers for lung cancer, we wanted to determine how the quotient of miR-9 divided by let-7 depends on the parameters of the model equations. We focused on the parameters in [Table 2](#pone-0053663-t002){ref-type="table"} which are only estimations. We performed sensitivity analysis, employing the method of partial rank correlation coefficient (PRCC), using previously described program [@pone.0053663-Marino1]. We let each of the parameters vary in the interval between of the estimated value and twice its estimated value. Using Latin Hypercube sampling method as in [@pone.0053663-Marino1], we sampled each parameter from uniformly distributed intervals and ran realizations of simulation. Then, we transformed the sampled parameter values and the ratio between miR-9 and let-7 as computed in the simulation to rank values, and computed partial rank correlation coefficients. PRCC values of the estimated parameters and their ranges are presented in [Table 3](#pone-0053663-t003){ref-type="table"}, and scatter plots of statistically significant parameters are shown in [Figure 15](#pone-0053663-g015){ref-type="fig"}.

![Scatter plots of rank transformed with several rank transformed parameters.\
Scatter plots are drawn for statistically significant parameters (p-value); the units on the horizontal and vertical axes are scaled in ; time is at minutes and the result is taken from realizations of simulation.](pone.0053663.g015){#pone-0053663-g015}

10.1371/journal.pone.0053663.t002

###### Summary of the parameter values.

![](pone.0053663.t002){#pone-0053663-t002-2}

  Name                   Description                  Value used           References
  ------ ------------------------------------------- ------------ -----------------------------
              concentration of EGF-EGFR complex                      [@pone.0053663-Brown1]
                         (constant)                               
                 total concentration of SOS                          [@pone.0053663-Brown1]
                 total concentration of Ras                          [@pone.0053663-Brown1]
                 total concentration of ERK                          [@pone.0053663-Brown1]
          Steady-state concentration of active SOS                          estimated
          Steady-state concentration of active Ras                          estimated
          Steady-state concentration of active ERK                          estimated
          Steady-state concentration of MYC protein                 [@pone.0053663-Rudolph1]
             Steady-state concentration of miR-9                            estimated
             Steady-state concentration of let-7                      [@pone.0053663-Lim1]
          Steady-state concentration of E-Cadherin                  [@pone.0053663-Chaplain1]
           Steady-state concentration of MMP mRNA                   [@pone.0053663-Safranek1]
          Saturation of inactive SOS on active SOS                   [@pone.0053663-Brown1]
          Saturation of active SOS on inactive SOS                   [@pone.0053663-Brown1]
          Saturation of inactive Ras on active Ras                   [@pone.0053663-Brown1]
                   Control of let-7 on Ras                                  estimated
          Saturation of active Ras on inactive Ras                   [@pone.0053663-Brown1]
          Saturation of inactive ERK on active ERK                   [@pone.0053663-Brown1]
          Saturation of active ERK on inactive ERK                   [@pone.0053663-Brown1]
                 Saturation of MYC on miR-9                                 estimated
                   Control of MYC on let-7                                  estimated
                Control of MYC on E-Cadherin                                estimated
              Control of E-Cadherin on MMP mRNA                             estimated
           Catalytic production rate of active SOS                   [@pone.0053663-Brown1]
           Catalytic production rate of active Ras                   [@pone.0053663-Brown1]
           Catalytic production rate of active ERK                   [@pone.0053663-Brown1]
              Catalytic production rate of MYC                              estimated
             Catalytic production rate of miR-9                             estimated
             Catalytic production rate of let-7                             estimated
           Catalytic production rate of E-Cadherin                          estimated
              Catalytic production rate of MMP                              estimated
               Degradation rate of active SOS                        [@pone.0053663-Brown1]
               Degradation rate of active Ras                        [@pone.0053663-Brown1]
               Degradation rate of active ERK                        [@pone.0053663-Brown1]
               Degradation rate of MYC protein                      [@pone.0053663-Luscher1]
                  Degradation rate of miR-9                          [@pone.0053663-Sethi1]
                  Degradation rate of let-7                        [@pone.0053663-Iliopoulos1]
               Degradation rate of E-Cadherin                        [@pone.0053663-Fujita1]
                Degradation rate of MMP mRNA                         [@pone.0053663-Akool1]

The table summarizes all the parameter values of the model [equations (1)](#pone.0053663.e014){ref-type="disp-formula"}--[(8)](#pone.0053663.e021){ref-type="disp-formula"}.

10.1371/journal.pone.0053663.t003

###### Parameter ranges and partial rank correlation coefficient (PRCC) values.

![](pone.0053663.t003){#pone-0053663-t003-3}

  Parameter    Range   PRCC
  ----------- ------- ------
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      

Statistically significant parameters are denoted as ^\*^ (p-value).

Among the parameters, , , , , , and were statistically significant. The parameters and were strongly positively correlated with . This is natural; indeed and are production rates of MYC and miR-9. As we increase production rate of MYC, miR-9 concentration increases and let-7 concentration decreases. On the other hand, , , and were strongly negatively correlated to . This is also to be expected. Indeed, is the production rate of let-7, is the saturation constant of MYC as source for miR-9, and is the control constant of MYC in the let-7 equation. Therefore, it is natural that would decrease as the parameters , , and increase. When we ran realizations of simulation, we obtained similar results.

EGFR inhibition reduces both c-MYC and miR-9 in a concentration dependent manner {#s2e}
--------------------------------------------------------------------------------

In an initial attempt to validate our mathematical model, we treated an EGFR mutant lung cancer cell line with several concentration of the clinically used EGFR inhibitor Gefitinib. We then assessed treated cells for miR-9, let-7a and c-MYC expression by QRT-PCR. As shown in [Figure 16](#pone-0053663-g016){ref-type="fig"}, we determined that while lower concentrations () of Gefitinib caused a statistically significant reduction in both miR-9 and c-MYC, similar effects were not evident at higher concentrations of Gefitinib or in let-7a. These findings while they would need to be validated in other cell lines suggest the additional complexity of the effects EGFR inhibition on miRNA expression and that our mathematical model only partially predicts the biological links between EGFR, c-MYC and miRNA in lung cancer.

![QRT-PCR expression of miR-9, let-7a and c-MYC in HCC827 lung cancer cell lines treated with Gefitinib.\
Statistical significance is defined as \**p*\<0.05 in (A) and \*\**p*\<0.01 in (C).](pone.0053663.g016){#pone-0053663-g016}

Discussion {#s3}
==========

Lung cancer is the leading cause of cancer-related deaths worldwide. The majority of cases are diagnosed at later stages thus limiting therapeutic options and contributing to poor outcome. As a result, investigators have sought to identify lung cancer specific biomarkers that may be utilized for early detection and to better understand the metastatic process. Such biomarkers may significantly improve prognosis and reduce mortality. In this paper, we have proposed a mathematical model that integrates the miRNAs let-7 and miR-9 into the process of EMT. miR-9 has been shown to be significantly upregulated and let-7 downregulated in NSCLC.

Based on the experimental literature, we introduced a signaling pathway from the EGF-EGFR complex to MMP expression which involves SOS, Ras, ERK, MYC, the miRNAs miR-9 and let-7, E-Cadherin, and MMP. Recent studies have demonstrated elevated MMP-9 in NSCLC [@pone.0053663-Zheng1], but for modeling purposes we have referred to MMP in a generic manner. Using an EGFR mutant lung cancer cell line, we showed that inhibition of EGFR leads to a reduction in miR-9 as well as c-MYC expression. However, the relationships between miR-9 and c-MYC were not consistent at higher concentrations of drug treatment. These findings support the complexity of the kinetics of miRNA and target gene relationships and highlight the inherent difficulties with modeling miRNA biology. Our findings suggest that higher concentrations of EGFR are likely to engage other regulators of miR-9 and/or c-MYC and that miR-9 may be under the regulatory control of additional genes beyond c-MYC.

We correspondingly developed a mathematical model including a system of differential equations and used the model to compute the level of miR-9 overexpression and let-7 downexpression in the setting of EGFR mutations and Ras mutations. We showed that such mutations upregulate the level of miR-9 and downregulate the level of let-7. The -fold increase in miR-9 levels obtained in the simulations was consistent quantitatively with clinical data reported in human lung tumors (Supplementary [Material S1](#pone.0053663.s001){ref-type="supplementary-material"}). Our experiments with EGFR mutant lung cancer cells did not show any significant changes in let-7 suggesting that let-7 may also be regulated by other signaling networks. We investigated how random perturbations of let-7 and miR-9 affect MMP and concluded that MMP is more robust against let-7 perturbations than against miR-9 perturbations; this can be explained by the fact that let-7 perturbations undergo damping by the negative feedbacks from let-7 to Ras and from ERK to SOS.

To the best of our knowledge, the present paper is the first one that develops a model for lung cancer and miRNA in terms of differential equations. The model is based on a signaling pathway that includes miR-9 and let-7. Simulations of the model demonstrate how mutations that are detected in NSCLC include upregulation of miR-9 and downregulation of let-7. The mathematical model could be further extended by including additional signaling pathways, specifically involving let-7, that are associated with lung cancer. However, an important next step in this line of investigation is to determine how deregulation of miR-9 and let-7 may jointly contribute to lung cancer progression and may be used as reliable biomarkers. In order to address this challenge mathematically, additional clinical investigation will be required.

Methods {#s4}
=======

In this model, we assume that the EGF-EGFR complex is at steady state and set it as a constant. Brown et al. (2004) modeled EGFR signaling with negative feedback of ERK to SOS [@pone.0053663-Brown1]. We simplified some parts of their model to obtain the equations for SOS, Ras, and ERK. We denote by , , and the concentrations of active SOS, inactive SOS, and total SOS, respectively. Assuming that the total number of SOS is conserved, we have

We denote by the activation rate of the inactive SOS and by as the deactivation rate of the active SOS. Describing these conversions by the Michaelis-Menten kinetics, the governing equation for the concentration of the active SOS is given by

Using the fact that the EGF-EGFR complex activates SOS and that ERK represses active SOS, we replace by and by , and we get [Eq. (1)](#pone.0053663.e014){ref-type="disp-formula"}. Similarly, we describe conversions between active and inactive Ras and between active and inactive ERK using Michaelis-Menten kinetics, and derive [Eqs. (2)](#pone.0053663.e015){ref-type="disp-formula"} and [(3)](#pone.0053663.e016){ref-type="disp-formula"}. Here, catalytic activation rates of Ras and ERK are proportional to active SOS and active Ras concentrations, respectively. In [Eq. (2)](#pone.0053663.e015){ref-type="disp-formula"}, repression by let-7 of the activation of Ras is described by an inhibition factor, . In [Eq. (4)](#pone.0053663.e017){ref-type="disp-formula"}, production of MYC is proportional to active ERK concentration. In [Eq. (5)](#pone.0053663.e018){ref-type="disp-formula"}, activation of miR-9 by MYC is described by the fourth-order Hill function, since MYC is a transcription factor and miR-9 activation may involve several enzymatic steps. In [Eq. (6)](#pone.0053663.e019){ref-type="disp-formula"}, let-7 production is inhibited by MYC. In [Eq. (7)](#pone.0053663.e020){ref-type="disp-formula"}, E-Cadherin production is proportional to let-7 concentration and is inhibited by miR-9. Throughout [Eqs. (4)](#pone.0053663.e017){ref-type="disp-formula"}--[(7)](#pone.0053663.e020){ref-type="disp-formula"}, degradation of species is described by linear mass action kinetics. Finally, in [Eq. (8)](#pone.0053663.e021){ref-type="disp-formula"} MMP is produced at constant rate and is degraded by E-Cadherin.

The parameters of [Eqs. (1)](#pone.0053663.e014){ref-type="disp-formula"}--[(8)](#pone.0053663.e021){ref-type="disp-formula"} are derived in the following subsections. Most of the parameters are taken from Brown et al. (2004) [@pone.0053663-Brown1]. In their model, they have taken the initial concentrations of all active signaling species to be zero, and the initial concentrations of all inactive signaling species to be except for MEK and ERK, whose concentrations were taken to be . As for the EGF-EGFR complex concentration, Brown et al (2004) [@pone.0053663-Brown1] assume it to be a variable but in our model, it is constant. This constant is chosen as the steady state concentration of the EGF-EGFR complex computed using their parameters.

Computation of {#s4a}
--------------

We denote by , , and the numbers of molecules of EGF, free EGFR, and EGF-EGFR complex, and by and the binding and unbinding rates for the EGF-EGFR complex. If is the total number of the EGFR molecules, then . Assuming that binding and unbinding of EGF and EGFR are balanced at steady state, we havewhich gives

According to Brown et al. (2004) [@pone.0053663-Brown1], and hence . We shall determine by converting into a unit of concentration. Lung cells size, however, vary up to -fold differences [@pone.0053663-Stone1]. We therefore use an "average" cell size by taking it to be the HeLa cell.

Since EGF and EGFR are located on the cell surface, we need to compute the cell surface area; we assume that the cells have spherical shape with radius . For HeLa cell, the total volume isaccording to Fujioka et al. (2006) [@pone.0053663-Fujioka1]. Hence and its surface area is

Converting the number of molecules of into concentration on the cell surface, we compute steady-state concentration of EGF-EGFR complex aswhere is the Avogadro\'s number, ; is the amount of a substance that contains as many entities as there are atoms in of , and is molar concentration (per liter),

Other parameters in the SOS equation {#s4b}
------------------------------------

Let and denote the numbers of active and inactive SOS molecules. According to Brown et al. (2004),where P90Rsk is a p90 ribosomal s6 kinase that inactivates SOS, and is the number of active P90Rsk molecules [@pone.0053663-Brown1]. In that paper, parameters are given as , , , and . Using these numbers, we determine our parameters by where is the volume of the cytoplasm in a HeLa cell. The total number of molecules of active P90Rsk was taken to be [@pone.0053663-Brown1]. Since the initial concentration of ERK, , corresponds to molecules, we get

The initial concentration of SOS (all inactive) was , which corresponds to molecules. We convert this number to concentration using the volume of the cytoplasm in a HeLa cell,

Parameters in the Ras equation {#s4c}
------------------------------

Let and denote the numbers of molecules of active and inactive Ras. From Brown et al. (2004),where and denote the numbers of molecules of active SOS and active Ras-Gap [@pone.0053663-Brown1]. In [@pone.0053663-Brown1], parameters are given as , , , and . Also, the number of molecules of active Ras-Gap is treated as a constant equal to . Accordingly, we determine our parameters by

For total Ras concentration, we convert the total number of Ras molecules in a cell obtained from [@pone.0053663-Brown1] to concentration using the volume of the cytoplasm in a HeLa cell,

Parameters in the ERK equation {#s4d}
------------------------------

Let and denote the numbers of molecules of active and inactive ERK. Following Brown et al. (2004),where and denote the numbers of molecules of active MEK and active PP2A [@pone.0053663-Brown1]. PP2A is protein phosphatase 2 which is an enzyme targeting proteins in oncogenic signaling pathways. In that paper, parameters are given as , , , and ; the initial total numbers of molecules of MEK and Ras are given as and , and the number of molecules of active PP2A is treated as a constant equal to . Therefore, we determine our parameters by

We convert the total number of ERK molecules, consisting of active and inactive ERK in a cell to concentration, using the volume of the cytoplasm in a HeLa cell, and set

Parameters in the MYC equation {#s4e}
------------------------------

Following Rudolph et al. (1999), there are c-MYC proteins in the nucleus [@pone.0053663-Rudolph1]. We convert this to concentration using the volume of the nucleus in a HeLa cell, . Treating this concentration as the steady-state concentration of MYC, we get

Half-life of c-MYC protein is [@pone.0053663-Luscher1]. We take the half-life of c-MYC as , and compute a degradation rate as

In steady state in [Eq. (4)](#pone.0053663.e017){ref-type="disp-formula"},where is the steady-state concentration of ERK. To determine , we first compute steady-state concentration of let-7. Following Lim et al. (2003), there are let-7 molecules in a human HeLa cell [@pone.0053663-Lim1], and we assume that this number is at steady state. We convert it to concentration by

We compute a solution of [Eq. (1)](#pone.0053663.e014){ref-type="disp-formula"}--[(3)](#pone.0053663.e016){ref-type="disp-formula"} for , , and with replaced by using Matlab, and obtain the steady-state concentration of ERK as . From [Eq. (14)](#pone.0053663.e482){ref-type="disp-formula"}, we then get

Parameters in the miR-9 equation {#s4f}
--------------------------------

Since the miR-9 copy number in the normal lung cell is very small [@pone.0053663-Liang1], we take the steady-state concentration of miR-9 to be . Half-life of miR-9 in human brain tissue is [@pone.0053663-Sethi1], which gives the degradation rate . In steady state in [Eq. (5)](#pone.0053663.e018){ref-type="disp-formula"},

Based on the fact that miR-9 expression in the NSCLC tissues is about times that of normal tissues (see Supplementary [Material S1](#pone.0053663.s001){ref-type="supplementary-material"}), we take to be very large, namely, . Then

Parameters in the let-7 equation {#s4g}
--------------------------------

Half-life of let-7 after TAM treatment is [@pone.0053663-Iliopoulos1]. Accordingly, we take the degradation rate of . Then, in steady state in [Eq. (6)](#pone.0053663.e019){ref-type="disp-formula"},

Taking gives

Parameters in the E-Cadherin equation {#s4h}
-------------------------------------

Using the total E-Cadherin concentration in Chaplain (2011) [@pone.0053663-Chaplain1], we set steady-state concentration, . Half-life of E-Cadherin is [@pone.0053663-Fujita1], so the degradation rate is . In steady state in [Eq. (7)](#pone.0053663.e020){ref-type="disp-formula"},

Taking gives

Parameters in the MMP mRNA equation {#s4i}
-----------------------------------

According to Safranek et al. (2009), the number of MMP-9 mRNA in human lung tissue is [@pone.0053663-Safranek1]. Using the human lung tissue density of [@pone.0053663-Hopkins1], we compute the MMP mRNA concentration in steady state,

Half-life of MMP-9 mRNA is [@pone.0053663-Akool1], so the degradation rate is . Using the steady state equation for MMP concentration,and taking , we get

Cell culture and drug treatment {#s4j}
-------------------------------

For our experiments shown in [Figure 16](#pone-0053663-g016){ref-type="fig"}, we obtained the EGFR mutant lung cancer cell line (HCC827) (E746-A750 deletion) as a generous gift from our collaborator (Michela Garofalo, OSU). Cells were maintained in appropriate media. HCC827 cell lines were subsequently treated with Gefitinib (generous gift from Michela Garofalo, OSU) at concentrations of , , and . Following hours of exposure, cells were harvested for RNA and assessed for miR-9 (Assay ID\# Hs000583), let-7a (Assay ID\# Hs00377), c-MYC (Assay ID\# Hs00153408_m1) (Applied Biosystems) by QRT-PCR. For miRNA assessment RNU48 was used as the endogenous control and for c-MYC GAPDH was used. Data is presented as fold difference based on . Statistical analyses were performed using ANOVA with Tukey Post Hoc analysis.

Supporting Information {#s5}
======================

###### 

**Experimental results of miR-9 in lung tumor tissues.** Experimental results using quantitative reverse transcription polymerase chain reaction and in situ hybridization for miR-9 are provided.

(PDF)

###### 

Click here for additional data file.
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